EGFR and glioblastoma: Cross-signaling between EGFR and EGFRvIII has been documented to contribute to GBM growth in vivo via increased CCL2 levels and activation of STAT3, a transcription factor enriched in the most aggressive mesenchymal subtype of GBMs [7,37,40].